biostudies-literatureUnknown129(3)Thavaneswaran SOHMR - Health Administration Corporation as represented by the Ministry of Health Commonwealth Government Grant (GO 1964) MRFF Emerging Priorities and Consumer Driven Research initiative<h4>Purpose</h4>To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects.<h4>Patients and methods</h4>In total, 48 patients were treated with O + D, 16 with BRCA1/2 alterations (group 1) and 32 with other select HRR alterations (group 2). Overall, 32 (66%) patients had rare or less common cancers. The primary objective of this single-arm Phase II trial was a progression-free survival rate at 6 months (PFS6). Post hoc exploratory analyses were conducted on archival tumour tissue and serial bloods.<h4>Results</h4>The PFS6 rate was 35% and 38% with durable objective tumour responses (OTR) in 3(19%) and 3(9%) in groups 1 and 2, respectiveBritish journal of cancer475-485https://www.ebi.ac.uk/biostudies/studies/S-EPMC10403555biostudies-literatureA signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.PMC10403555Mundra PGrady JPSchmitz USebastian LJoshua AMThomas DMSimes JCorpuz TLee CKBallinger MLEspinoza DKansara MLin FThavaneswaran SBailey CGQiu MRfalseA signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.<h4>Purpose</h4>To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects.<h4>Patients and methods</h4>In total, 48 patients were treated with O + D, 16 with BRCA1/2 alterations (group 1) and 32 with other select HRR alterations (group 2). Overall, 32 (66%) patients had rare or less common cancers. The primary objective of this single-arm Phase II trial was a progression-free survival rate at 6 months (PFS6). Post hoc exploratory analyses were conducted on archival tumour tissue and serial bloods.<h4>Results</h4>The PFS6 rate was 35% and 38% with durable objective tumour responses (OTR) in 3(19%) and 3(9%) in groups 1 and 2, respective2023-01-01T00:00:00Z2023 Aug2025-04-05T00:24:14.486Z2025-04-05T00:24:14.486ZS-EPMC104035553736528410.1038/s41416-023-02311-0